2026-02-24T14:46:12-05:00 2025-09-30 461041593 FINANCIAL SOLUTION ADVISORS LLC 4350 PABLO PROFESSIONAL CT STE 200 JACKSONVILLE FL 32224 990 2024-10-01 453710305 IDAHO VETERANS RESEARCH & EDUCATION FOUNDATION IDAH 2084221000 500 W FORT STREET BLDG 117 BOISE ID 83702 MARGARET K ALDAPE EXECUTIVE DIRECTOR 2084221000 2026-02-24 true MICHAEL B MCLEOD CPA P00966646 9042962024 2026-02-24 2024 2025-03-06 01:10:19Z MARGARET K ALDAPE 500 W FORT STREET BLDG 117 BOISE ID 83702 1139352 false X WWW.IVREF.ORG X 2011 ID TO ADVANCE THE RESEARCH AND EDUCATION MISSION OF THE DEPARTMENT OF VETERANS AFFAIRS AND SPECIFICALLY THE BOISE VA MEDICAL CENTER THROUGH THE SUPPORT OF RESEARCH AND EDUCATION RELATED ACTIVITIES. 7 7 15 0 480899 299779 617920 830983 17281 8338 2108 252 1118208 1139352 0 0 689757 762180 0 0 442774 413988 1132531 1176168 -14323 -36816 661046 626538 51986 56830 609060 569708 X TO ADVANCE THE RESEARCH AND EDUCATION MISSION OF THE DEPARTMENT OF VETERANS AFFAIRS AND SPECIFICALLY THE BOISE VA MEDICAL CENTER THROUGH THE SUPPORT OF RESEARCH AND EDUCATION RELATED ACTIVITIES. false false 944609 830983 EXPENDITURES RELATED TO RESEARCH AND EDUCATION. RESEARCH EXPENSES ASSOCIATED WITH THE FOLLOWING MAJOR GRANT PROJECTS: 1)NIH (U OF IDAHO SUB-AWARD) - IDAHO INBRE PROGRAM IVREF DOUCETTE 2)NIH (U OF IDAHO SUB-AWARD) - DHHS NIH INBRE4 IVREF HOBDEY DRP 3)NIH R21 - ROLE OF MIR-181A-5P IN ADENOVIRUS 14P1 INDUCED ACUTE LUNG INJURY 4)NIH RO3 - DEVELOPMENT OF ANTIBODIES TO SPECIFIC CELL SURFACE MARKERS TO ASSESS MACROPHAGE POLARIZATION DURING ADENOVIRUS 14 AND 14P1 INFECTION IN THE SYRIAN HAMSTER. 5) NIH (U OF PITTSBURGH SUB-AWARD) - MACS/WIHS CCS KUNISAKI 6)PCORI (SIBCR SUB-AWARD) - FUNCTIONAL IMPROVEMENT IN OSA AND COPD WITH A TELEHEALTH LIFESTYLE AND EXERCISE INTERVENTION (FOCUSED) 7)PARATEK PHARMACEUTICALS - INVESTIGATING THE ANTI-INFLAMMATORY ACTIVITIES OF OMADACYCLINE 8)ALTO PHARMACEUTICALS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER. 9)JANSSEN RESEARCH & DEVELOPMENT - MULTICOHORT STUDY TO CUSTOMIZE IBRUTINIB TREATMENT REGIMENS FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA 10)FERRING PHARMACEUTICALS - A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN- LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC ALONE OR IN COMBINATION WITH CHEMOTHERAPY (GEMCITABINE AND DOCETAXEL) OR IMMUNOTHERAPY (PEMBROLIZUMAB) IN SUBJECTS WITH HIGH-GRADE BACILLUS CALMETTE-GUERIN (BCG) UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) 11)STABILITY BIOLOGICS - A MULTICENTER, PROSPECTIVE, RANDOMIZED CONTROLLED MODIFIED MULTI-PLATFORM (MATRIARCH) TRIAL EVALUATING SEVERAL CELLULAR, ACELLULAR, AND MATRIX-LIKE PRODUCTS (CAMPS) AND STANDARD OF CARE VERSUS STANDARD OF CARE ALONE IN THE MANAGEMENT OF NONHEALING DIABETIC FOOT AND VENOUS LEG ULCERS 944609 true true false false false false false false false false true false false false false true true false false false false false false false false false false false false false false false false false false false false false false false false false false true false false false true 1 0 15 true false false false false false false false false false false false false false false X 7 7 false false false false false true true true true false false true true true false false false true false false ID X MICAH ROOS 2084221000 500 WEST FORT STREET BLDG 117 BOISE ID 83702 MARGARET K ALDAPE EXECUTIVE DI 40.00 X 85606 0 0 MICAH ROOS CFO 40.00 X 78011 0 0 MARTIN BLAIR DIRECTOR 10.00 X 0 0 0 MARGARET DOUCETTE PRESIDENT 10.00 X X 0 0 0 AMBER FISHER DIRECTOR 10.00 X 0 0 0 ANDREW WILPER VICE PRESIDE 10.00 X X 0 0 0 DAVID WOOD CHAIRMAN 10.00 X X 0 0 0 ROBERT WOOD SECRETARY 10.00 X 0 0 0 JANET HINES TREASURER 10.00 X 0 0 0 163617 false false false 80718 219061 299779 CLINICAL TRIAL REVENUES 541700 552554 552554 IPA REIMBURSEMENT REVENUES 541700 245262 245262 ADMINISTRATIVE REVENUES 541700 29100 29100 PHARMACY FEES 541700 4067 4067 830983 8338 8338 CREDIT CARD REWARDS 252 252 252 1139352 831235 8338 178135 178135 496215 492287 3928 34528 34528 53302 40031 13271 1440 480 960 12250 12250 10685 10685 553 148 405 240 240 11783 10035 1748 4490 2808 1682 36199 36199 3170 3170 RESEARCH SRVCS REIMB 207132 207132 RESEARCH SUPPLIES 104992 104992 DUES AND SUBSCRIPTIONS 13429 8344 5085 SUBJECT PATIENT EXPENSE 4543 4543 3082 3082 1176168 944609 231559 0 121964 166940 204690 202150 203273 167419 16341 11450 713274 634695 114778 78579 661046 626538 51986 56830 51986 56830 X 609060 569708 609060 569708 661046 626538 X -36816 -2540 4 X false true X true false X 1730851 1406022 708008 480899 299779 4625559 292215 354200 351189 354200 357211 1709015 2023066 1760222 1059197 835099 656990 6334574 183905 6150669 733 9721 17281 8338 36073 4934 4391 101 2108 252 11786 6382433 1483643 0.96370 0.99350 X PART II, LINE 10 OTHER INCOME 11,786 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 713274 634695 78579 78579 X 1494023 -2540 357211 354671 1139352 1139352 1533379 357211 357211 1176168 1176168 SCHEDULE D, PAGE 3, PART X THE ORGANIZATION QUALIFIES AS A TAX-EXEMPT ORGANIZATION UNDER SECTION 501 (C)(3) OF THE INTERNAL REVENUE CODE. THE ORGANIZATION PERIODICALLY ASSESSES WHETHER IT HAS INCURRED INCOME TAX EXPENSE OR RELATED INTEREST OR PENALTIES IN ACCORDANCE WITH ACCOUNTING FOR UNCERTAIN TAX POSITIONS. NO SUCH AMOUNTS WERE RECOGNIZED FOR THE YEARS ENDING SEPTEMBER 30, 2025 AND 2024, RESPECTIVELY. THE ORGANIZATION FOLLOWS THE INCOME TAX STANDARD FOR UNCERTAIN TAX POSITIONS. THE ORGANIZATION HAS EVALUATED THEIR TAX POSITIONS AND DETERMINED THEY HAVE NO UNCERTAIN TAX POSITIONS AS OF SEPTEMBER 30, 2025 AND 2024. SHOULD THE ORGANIZATIONS TAX-EXEMPT STATUS BE CHALLENGED IN THE FUTURE, THE ORGANIZATIONS 2023, 2024, AND 2025 TAX YEARS ARE OPEN FOR EXAMINATION BY THE IRS. FORM 990, PAGE 2, PART III, LINE 4A EXPENDITURES RELATED TO RESEARCH AND EDUCATION. RESEARCH EXPENSES ASSOCIATED WITH THE FOLLOWING MAJOR GRANT PROJECTS: 1)NIH (U OF IDAHO SUB-AWARD) - IDAHO INBRE PROGRAM IVREF DOUCETTE 2)NIH (U OF IDAHO SUB-AWARD) - DHHS NIH INBRE4 IVREF HOBDEY DRP 3)NIH R21 - ROLE OF MIR-181A-5P IN ADENOVIRUS 14P1 INDUCED ACUTE LUNG INJURY 4)NIH RO3 - DEVELOPMENT OF ANTIBODIES TO SPECIFIC CELL SURFACE MARKERS TO ASSESS MACROPHAGE POLARIZATION DURING ADENOVIRUS 14 AND 14P1 INFECTION IN THE SYRIAN HAMSTER. 5) NIH (U OF PITTSBURGH SUB-AWARD) - MACS/WIHS CCS KUNISAKI 6)PCORI (SIBCR SUB-AWARD) - FUNCTIONAL IMPROVEMENT IN OSA AND COPD WITH A TELEHEALTH LIFESTYLE AND EXERCISE INTERVENTION (FOCUSED) 7)PARATEK PHARMACEUTICALS - INVESTIGATING THE ANTI-INFLAMMATORY ACTIVITIES OF OMADACYCLINE 8)ALTO PHARMACEUTICALS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER. 9)JANSSEN RESEARCH & DEVELOPMENT - MULTICOHORT STUDY TO CUSTOMIZE IBRUTINIB TREATMENT REGIMENS FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA 10)FERRING PHARMACEUTICALS - A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN- LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC ALONE OR IN COMBINATION WITH CHEMOTHERAPY (GEMCITABINE AND DOCETAXEL) OR IMMUNOTHERAPY (PEMBROLIZUMAB) IN SUBJECTS WITH HIGH-GRADE BACILLUS CALMETTE-GUERIN (BCG) UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) 11)STABILITY BIOLOGICS - A MULTICENTER, PROSPECTIVE, RANDOMIZED CONTROLLED MODIFIED MULTI-PLATFORM (MATRIARCH) TRIAL EVALUATING SEVERAL CELLULAR, ACELLULAR, AND MATRIX-LIKE PRODUCTS (CAMPS) AND STANDARD OF CARE VERSUS STANDARD OF CARE ALONE IN THE MANAGEMENT OF NONHEALING DIABETIC FOOT AND VENOUS LEG ULCERS FORM 990, PAGE 6, PART VI, LINE 7A VA DIRECTORS ARE EX-OFFICIO PER THE ORGANIZATION'S BY-LAWS. OTHER DIRECTORS AND OFFICERS ARE ELECTED BY A MAJORITY VOTE OF THE BOARD OF DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 7B ARTICLES AND BY-LAWS DICTATE THAT CERTAIN ACTIONS MAY BE TAKEN BY A MAJORITY VOTE OF THE VA DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF THE FORM 990 IS AVAILABLE TO ALL DIRECTORS PRIOR TO FILING OF THE RETURN. THE EXECUTIVE DIRECTOR AND CHIEF FINANCE OFFICER REVIEWS THE FORM 990 BEFORE SIGNING AND REPORTS ANY ITEMS OF CONCERN TO THE OTHER DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 15A THE BOARD OF DIRECTORS ARE RESPONSIBLE FOR DETERMINING, REVIEWING, AND APPROVING THE EXECUTIVE DIRECTOR'S COMPENSATION. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REASONABLE WRITTEN REQUEST FOR SUCH INFORMATION. FORM 990, PART XI, LINE 9 ROUNDING 4 BEGINNING NET ASSETS AS OF SEPTEMBER 30, 2024 HAVE BEEN RECLASSIFIED BY 48,7844 FROM NET ASSETS WITH DONOR RESTRICTIONS TO NET ASSETS WITHOUT DONOR RESTRICTIONS. THIS RECLASSIFICATION AFFECTS PRESENTATION ONLY AND DOES NOT CHANGE TOTAL NET ASSETS. BOISE VA MEDICAL CENTER 500 WEST FORT STREET BOISE ID 83702 820465077 V.A CENTER ID US GOV NA false false false false false false false false false false false false false false true false true false false false BOISE VA MEDICAL CENTER N 357000 FAIR VALUE BOISE VA MEDICAL CENTER P 207000 CASH